Using in vitro experiments, investigators found that anlotinib had significant effects on proliferation inhibition, migration and invasion restraint, and cell-cycle arrestment in intrahepatic cholangiocarcinoma.
[Cell Death & Disease]
Song, F., Hu, B., Cheng, J.-W., Sun, Y.-F., Zhou, K.-Q., Wang, P.-X., Guo, W., Zhou, J., Fan, J., Chen, Z., & Yang, X.-R. (2020). Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death & Disease, 11(7), 1–14. https://doi.org/10.1038/s41419-020-02749-7 Cite
0
